Rather, the biogeographical groups should help to roughly estimate the CYP2D6 functionality-related risk for subtarget CSS,min ENDX in different breast cancer populations and highlight populations with highest need for personalized dosing. This evidence concerns the gene CYP2D6 and breast carcinoma.